Dynastat

Dynastat

parecoxib

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Parecoxib Na
Indications/Uses
Management of post-op pain in immediate post-op setting only.
Dosage/Direction for Use
Management of acute pain Initially 40 mg IV/IM, followed by 20 or 40 mg every 6-12 hr up to max: 80 mg daily. Elderly <50 kg Initially ½ usual dose. Max: 40 mg daily.
Contraindications
Hypersensitivity to parecoxib, sulfonamides, acetylsalicylic acid or NSAIDs including COX-2 inhibitors. Active peptic ulceration or GI bleeding; inflammatory bowel disease. CHF (NYHA II-IV). Treatment of post-op pain following CABG surgery. Established ischaemic heart disease, peripheral arterial disease &/or cerebrovascular disease. Severe hepatic impairment (serum albumin <25 g/L or Child-Pugh score ≥10). 3rd trimester of pregnancy. Lactation.
Special Precautions
Hypersensitivity to sulfonamides. Discontinue use at 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Serious skin reactions eg, erythema multiforme, Stevens-Johnson syndrome, hypersensitivity reactions, drug reaction w/ eosinophilia & systemic symptoms syndrome. Increased risk of CV & thromboembolic adverse events; history of active GI disease eg, ulceration, bleeding or inflammatory conditions; severe hypotension; HTN. Patients w/ compromised cardiac function, preexisting edema or other conditions predisposed to or worsened by fluid retention, or at risk of hypovolemia. Ensure adequate hydration. Avoid use w/ non-specific NSAIDs. Concomitant use w/ fluconazole, aspirin, corticosteroids, SSRIs, other antiplatelets & NSAIDs, oral anticoagulants, diuretics; alcohol. Not recommended in severe hepatic impairment. Advanced renal disease; severe renal impairment (CrCl <30 mL/min). Moderate hepatic impairment (Child-Pugh class B). Not recommended in women of childbearing potential. Not to be given during 1st & 2nd trimester of pregnancy. Lactation. Childn <18 yr. Elderly.
Adverse Reactions
Nausea. Abdominal pain, constipation, dyspepsia, vomiting; peripheral edema; alveolar osteitis; dizziness; insomnia; oliguria; increased sweating, pruritus; hypotension. Dry mouth, flatulence; back pain; bradycardia; pharyngitis; rash; HTN.
Drug Interactions
Increased AUC w/ known CYP3A4 & 2C9 inhibitors. Increased risk of bleeding w/ oral anticoagulants eg, warfarin. Enhanced AUC by fluconazole, ketoconazole. Diminished effect of ACE inhibitors, AIIA, β-blockers, diuretics. Deteriorated renal function w/ ACE inhibitors &/or AIIA. Reduced natriuretic effect of furosemide, thiazides. Increased risk of nephrotoxicity w/ cyclosporine. Increased methotrexate plasma levels. Decreased lithium serum & renal clearance.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AH04 - parecoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.
Presentation/Packing
Form
Dynastat powd for inj (vial) 40 mg
Packing/Price
10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in